Guided Therapeutics Stock Probability of Future OTC Stock Price Finishing Under 0
| GTHP Stock | USD 0.19 0.03 18.75% |
Guided |
Guided Therapeutics Target Price Odds to finish below 0
The tendency of Guided OTC Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to drop to $ 0.00 or more in 90 days |
| 0.19 | 90 days | 0.00 | near 1 |
Based on a normal probability distribution, the odds of Guided Therapeutics to drop to $ 0.00 or more in 90 days from now is near 1 (This Guided Therapeutics probability density function shows the probability of Guided OTC Stock to fall within a particular range of prices over 90 days) . Probability of Guided Therapeutics price to stay between $ 0.00 and its current price of $0.19 at the end of the 90-day period is about 82.03 .
Given the investment horizon of 90 days Guided Therapeutics has a beta of -0.95. This usually indicates In addition to that Guided Therapeutics has an alpha of 2.0259, implying that it can generate a 2.03 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Guided Therapeutics Price Density |
| Price |
Predictive Modules for Guided Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Guided Therapeutics. Regardless of method or technology, however, to accurately forecast the otc stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the otc stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Guided Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Guided Therapeutics is not an exception. The market had few large corrections towards the Guided Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Guided Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Guided Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 2.03 | |
β | Beta against Dow Jones | -0.95 | |
σ | Overall volatility | 0.02 | |
Ir | Information ratio | 0.11 |
Guided Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Guided Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Guided Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Guided Therapeutics is way too risky over 90 days horizon | |
| Guided Therapeutics has some characteristics of a very speculative penny stock | |
| Guided Therapeutics appears to be risky and price may revert if volatility continues | |
| Guided Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Guided Therapeutics currently holds 1.43 M in liabilities with Debt to Equity (D/E) ratio of 0.6, which is about average as compared to similar companies. Guided Therapeutics has a current ratio of 0.18, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Guided Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Guided Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Guided Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Guided to invest in growth at high rates of return. When we think about Guided Therapeutics' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 81 K. Net Loss for the year was (2.07 M) with profit before overhead, payroll, taxes, and interest of 20 K. | |
| Guided Therapeutics currently holds about 446 K in cash with (1.59 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| Roughly 40.0% of Guided Therapeutics shares are held by company insiders |
Guided Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Guided OTC Stock often depends not only on the future outlook of the current and potential Guided Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Guided Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 13.7 M |
Guided Therapeutics Technical Analysis
Guided Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Guided OTC Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Guided Therapeutics. In general, you should focus on analyzing Guided OTC Stock price patterns and their correlations with different microeconomic environments and drivers.
Guided Therapeutics Predictive Forecast Models
Guided Therapeutics' time-series forecasting models is one of many Guided Therapeutics' otc stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Guided Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the otc stock market movement and maximize returns from investment trading.
Things to note about Guided Therapeutics
Checking the ongoing alerts about Guided Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Guided Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Guided Therapeutics is way too risky over 90 days horizon | |
| Guided Therapeutics has some characteristics of a very speculative penny stock | |
| Guided Therapeutics appears to be risky and price may revert if volatility continues | |
| Guided Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Guided Therapeutics currently holds 1.43 M in liabilities with Debt to Equity (D/E) ratio of 0.6, which is about average as compared to similar companies. Guided Therapeutics has a current ratio of 0.18, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Guided Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Guided Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Guided Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Guided to invest in growth at high rates of return. When we think about Guided Therapeutics' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 81 K. Net Loss for the year was (2.07 M) with profit before overhead, payroll, taxes, and interest of 20 K. | |
| Guided Therapeutics currently holds about 446 K in cash with (1.59 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| Roughly 40.0% of Guided Therapeutics shares are held by company insiders |
Additional Tools for Guided OTC Stock Analysis
When running Guided Therapeutics' price analysis, check to measure Guided Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Guided Therapeutics is operating at the current time. Most of Guided Therapeutics' value examination focuses on studying past and present price action to predict the probability of Guided Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Guided Therapeutics' price. Additionally, you may evaluate how the addition of Guided Therapeutics to your portfolios can decrease your overall portfolio volatility.